Research
Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation
Science · By Lena Morrill Gavarró, Monica F. Chen, Álvaro Quintanal Villalonga, Yufei Deng, Liancheng Lu, Britney Forsyth, Sahil Sahni, Eric G. Sun, Swanand Rakhade, Rania G. Aly, Amin Sabet, Prithviraj Solanki, Christina Wilson, Natasha Rekhtman, Sam Tischfield, Jake June-Koo Lee, Khadeja Moses, Linda Ahn, Clare Wilhelm, Amanda Pupo, Christina Falcon, Andrea Arfe, Katherine Panageas, Mark G. Kris, Parvathy Manoj, Ignas Masilionis, Ojasvi Chaudhary, Ronan Chaligne, Esther Redin, Eric Gardner, Xinjun Wang, Dana Pe’er, Charles M. Rudin, Joseph M. Chan & Helena A. Yu ·
The Brief
- A study in Science Translational Medicine examines osimertinib combined with platinum and etoposide.
- It targets metastatic lung cancers with EGFR, TP53 and RB1 mutations that are at risk of histological transformation.
- The article was published in Volume 18, Issue 875 of the journal in November 2026.
Why it matters
It addresses a specific high-risk group of lung cancer patients, where the tumour may change type and become harder to treat, and tests a combination therapy for them.
Who’s affected
- oncologists treating EGFR-mutant lung cancer
- patients with metastatic EGFR/TP53/RB1-mutant lung cancer
- #lung cancer
- #osimertinib
- #egfr mutation
- #histological transformation
- #oncology
Science Translational Medicine, Volume 18, Issue 875 , November 2026.
Timeline
Published in Science Translational Medicine, Volume 18, Issue 875
science.org
Osimertinib, platinum, and etoposide for patients with metastatic EGFR/TP53/RB1-mutant lung cancers at risk for histological transformation